Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial.
暂无分享,去创建一个
A. Tinker | R. Wenham | D. Provencher | U. Matulonis | Susana Banerjee | P. Follana | M. Mirza | P. Harter | R. Shapira-Frommer | F. Goffin | I. Bover | M. Fabbro | S. Mahner | A. Dørum | K. Hellman | G. Tognon | M. Pineda | S. Banerjee | S. Hazard | K. Moore | I. Vazquez
[1] K. Moore,et al. Tolerance and toxicity of the PARP inhibitor olaparib in older women with epithelial ovarian cancer. , 2017, Gynecologic oncology.
[2] A. Secord,et al. Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer - An NRG oncology/Gynecologic Oncology Group study. , 2017, Gynecologic oncology.
[3] Susana Banerjee,et al. Improving outcomes for older women with gynaecological malignancies. , 2016, Cancer treatment reviews.
[4] Ignace Vergote,et al. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. , 2016, The New England journal of medicine.
[5] F. Chauvin,et al. Prognostic factors for overall survival in elderly patients with advanced ovarian cancer treated with chemotherapy: Results of a pooled analysis of three GINECO phase II trials. , 2016, Gynecologic oncology.
[6] G. Fleming,et al. The Application and Outcome of Standard of Care Treatment in Elderly Women with Ovarian Cancer: A Literature Review over the Last 10 Years , 2016, Front. Oncol..
[7] M. Brady,et al. Age as a prognostic factor in ovarian carcinoma: The gynecologic oncology group experience , 2010, Cancer.
[8] A. Levine,et al. Declining p53 function in the aging process: A possible mechanism for the increased tumor incidence in older populations , 2007, Proceedings of the National Academy of Sciences.
[9] S. Loibl,et al. Feasibility, toxicity and quality of life of first-line chemotherapy with platinum/paclitaxel in elderly patients aged >or=70 years with advanced ovarian cancer--a study by the AGO OVAR Germany. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[10] M. Markman,et al. Treatment patterns by decade of life in elderly women (> or =70 years of age) with ovarian cancer. , 2005, Gynecologic Oncology.
[11] M. Extermann,et al. Management of cancer in the older person: a practical approach. , 2000, The oncologist.
[12] U. Matulonis,et al. Niraparib in Recurrent Ovarian Cancer. , 2017, New England Journal of Medicine.
[13] F. Chauvin,et al. Prognostic Factors for Overall Survival in Elderly Patients With Advanced Ovarian Cancer Treated With Chemotherapy: Results of a Pooled Analysis of Three GINECO Phase II Trials , 2017 .
[14] W. Tew,et al. Treatment and trials: ovarian cancer in older women. , 2013, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.